Derm systemic meds Flashcards
DCNP (35 cards)
Cyclosporine start labs
-two baseline BPs at least a day apart
-CBC w/ diff & CMP
-Two baseline creatinine level (or Cr clearance) at least a day apart
Cyclosporine contraindications
-CTCL
-abn renal function
-uncontrolled HTN
-malignancies
-radiation therapy or concomitant PUVA/UVB
-MTX or immunosuppressives
Cyclosporine pregnancy
Category C; new 2015 rating; probably compatible
Cyclosporine warnings
-nephrotoxicity, hepatotoxicity, serous infections, transplantation patients (^malignancy)
-HTN, usually mild and generally reversible after dose reduced or d/c
Corticosteroids contraindicated
-systemic fungal infections, hypersensitivity
-live vax shouldn’t be given
Corticosteroids >4 weeks
-DEXA scan, Vit D 800 IU, calcium 1,200 mg, biphosphonates
- >1 gm total dose H2 antihistamines or PPIs
MTX absolute C/I
-ETOH abuse, bone marrow d/o, CKD, liver dz, immuondeficiency syndromes, patients contemplating pregnancy and lactation
MTX drug interactions HIGH risk
sulfonamides (dapsone),sulfamethoxazole (TMP/SMX), phenytoin, phenothiazine, NSAIDs, immunosuppressants, oral retinoids
MTX drug interactions LOWer risk
tetracyclines, cholestyramine, live vax
MTX warnings
-complete vax (live or recombinant) 2 wks before initiation of treatment
-monitor for preg/BF
-screen/monitor for infection
-assessment of ETOH intake
MTX adverse effects
Hepatotoxicity, aplastic anemia, pancytopenia, GI sx (diarrhea, stomatitis, intestinal perforation), opportunistic or reactivation of infections, secondary malignancies. MTX pneumonitis (usu. in first 6 mons dry cough, SOB)
MTX labs
Baseline: CBC w/ diff, liver/renal fxn, screen Hep B/C, TB, HIV if indicated
Follow-up: CBC & LFTs 1 wk after test dose, then q1-2 wks for month, then q3-4mons, renal fxn 1-2 yearly
MTX liver evaluation
Baseline only if high-risk (NASH, obesity, HLD)
1st bx 3.5-4 g total cumulative
General biologics guidelines
-baseline screen for infections (Tb, Hep B/C, HIV)
-don’t use on pts w/ acute/chronic infection
-avoid all live vax during tpy
-d/c if hypersensitivity, or serious infections
Biologics: special pops
-Hepatitis B, eval by GI spec
-Hep C, confirmed and resolved (may use anti-TNF, monitor for reactivations)
-Preg/lact, greatest r/o placental transfer 3rd tri; anti-TNF safest certolizumab pegol
-Etanercept ages 4 and older
-don’t use MTX, acetretin & top tazarotene, C/i preg
Biologics: Target specific safety issues
TNFa inhibitors: TB, NYHA III/IV HF, lupus, MS
IL-17 inh: candida infections, IBD
IL-12/23 ustekinumab (Stelara): exfoliative dermatitis
IL-23 p19: none
Antivirals therapeutic recommendations
(acyclovir, valacyclovir, famciclovir)
indications for HSV & HZ
-may cause nephrotox (intratubular precipitation of crystals)
- ^ risk if dehydration or pre-exis renal impairment
-f/u vax should be delayed at least 2 wks p antiviral tpy
Zoster antiviral dosing
acyclovir: 800 mg 5x/day x 7-10 d
valacyclovir*: 1 g TID x 7-10 d
famciclovir: 500 mg TID x 7d
HSV primary episode
acyclovir: 400 mg TID x 10 d
valacyclovir: 1 g BID x 10 d
famciclovir: 250 mg TID x 10d
Itraconazole contraindication
ventricular dysfunction (CHF)
Oral ketoconazole
black box warning: serious hepatoxoticity
QT Prolongation
Oral terbinafine
AE rare but severe neutropenia and noted smell and taste disturbance
MRSA susceptible abx
clindamycin, bactrim, tetracycline
Tetracyclines
-risk of pseudotumor cerebri alone or w/ isotretinoin, SJS/TEN, GI upset, esophagitis, vaginal candidiasis
-MCN: vestibular SE more common first few doses >F, dyspigmentation, DRESS, lupus-like syndrome, vasculitis